Updated data from ongoing clinical trial evaluating first-in-class antibody, IPH4102 will be presented at the EORTC CLTF 2018 Meeting in St Gallen, Switzerland, September 27-29, 2018.

- Title: IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
- Date and time: September 29, 2018, 8:30 - 9:45
- Presentation number: 078
- Session: Oral presentation, Session 8 / Treatment and clinical cases
- Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France
- Location: Olma Messen Hall 9.2, St-Gallen, Switzerland

Attachments

  • Original document
  • Permalink

Disclaimer

Innate Pharma SA published this content on 27 September 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 September 2018 08:55:05 UTC